1. Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns
2. US Food and Drug Administration. Updated information: June 9, 2023: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement. 9 Jun 2023. https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-information-june-9-2023-meeting-peripheral-and-central-nervous-system-drugs-advisory
3. Lecanemab in Early Alzheimer’s Disease
4. US Food and Drug Administration. Highlights of prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s001lbl.pdf
5. Eisai. Eisai submits marketing authorization application for lecanemab as treatment for early Alzheimer’s disease in Great Britain. 22 May 2023. https://www.eisai.com/news/2023/news202336.html